PHILADELPHIA, Aug. 22, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE AMEX:HEB) announced that investigators from the Tumor Vaccine Group (TVG) at the University of Washington in Seattle, WA, have enrolled their first patient in their 88 patient “Phase I-II Study of HER2 Vaccination With Poly(I) - Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients.”
